Company Name:Seattle Genetics Inc.
CEO: Clay B. Siegall

Sector: Healthcare
Industry:Biotechnology

Exchange: Nasdaq Global Select

Country: USA

Description: Seattle Genetics Inc is a biotechnology company. The company is focused on development and commercialization of targeted therapies for the treatment of cancer. Its products are ADCETRIS (brentuximab vedotin) US and ADCETRIS (brentuximab vedotin) Canada.


Key numbers

Market Capitalization:19666543500
Shares Outstanding: 171386000
Float: 169440426.12800002
Next Earning Date:2020-02-13
TTm EPS: -1.8684
TTm Dividend Rate:
200 days moving average:76.04
50 days moving average: 89.28
One day percent Change: 11.82



2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31,
2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,